NEW YORK (GenomeWeb News) – Molecular diagnostics firm Inostics announced today that its clinical laboratory in Baltimore, Md., has received CLIA licensure, allowing it to offer its non-invasive OncoBeam tumor mutation test.
The blood-based test is based on Beaming — or Beads, Emulsions, Amplification, and Magnetics — technology that combines emulsion-based digital PCR with flow cytometry. Inostics said the technology allows for the molecular analysis of tumor DNA shed from primary and metastatic tumors found circulating in a patient's blood.
"Due to the non-invasiveness and real-time reflection of tumor genetics, the OncoBEAM blood test represents a valuable tool to complement clinical decision making," Frank Diehl, CSO of Inostics, said in a statement.
Inostics is based in Hamburg, Germany and specializes in mutation detection. Aside from the Beaming technology, its other main technology is Plasma-Sequencing which uses next-generation sequencing technology for detecting mutations in plasma DNA.